drugset

Drugs / CST-103

Follow last change Mar 2025 re-read 3 minutes ago

CST-103

Developed for: parkinsonian disorder
Investigated by: CuraSen Therapeutics, Inc.

Trials 1

today NCT04935762 · Ph 2

20252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT04935762	Jun → Dec 2024	parkinsonian disorder	CuraSen Therapeutics, Inc.	Withdrawn	No outcome recorded Stop: Business

News releases announcing trial results or a regulatory action · 3

Date	Issuer	Release
2023-03-30	CuraSen Therapeutics, Inc.	Results CuraSen Therapeutics to Present Phase 2 Data Showing Rapid-Onset Cognition and Mood Benefit with CST-103/CST-107 (Clenbuterol/Nadolol) in Parkinson’s Disease at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD’23) Conference curasen.com ↗
2022-12-19	CuraSen Therapeutics, Inc.	Results CuraSen Therapeutics Announces Successful Completion of Phase 2 Safety, Tolerability and Proof of Concept Study in Patients with Parkinson’s Disease or Mild Cognitive Impairment (MCI) with CST-103/CST-107 Treatment curasen.com ↗ CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced today positive top-line safety, tolerability and proof of concept data, with early efficacy benefit, in a Phase 2 clinical trial with CST-103 in patients with Parkinson’s disease (PD) or mild cognitive impairment (MCI).
2021-11-09	CuraSen Therapeutics, Inc.	Results CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease curasen.com ↗

All press releases naming this drug 3 releases

Date	Issuer	Release
2023-03-30	CuraSen Therapeutics, Inc.	CuraSen Therapeutics to Present Phase 2 Data Showing Rapid-Onset Cognition and Mood Benefit with CST-103/CST-107 (Clenbuterol/Nadolol) in Parkinson’s Disease at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD’23) Conference curasen.com ↗
2022-12-19	CuraSen Therapeutics, Inc.	CuraSen Therapeutics Announces Successful Completion of Phase 2 Safety, Tolerability and Proof of Concept Study in Patients with Parkinson’s Disease or Mild Cognitive Impairment (MCI) with CST-103/CST-107 Treatment curasen.com ↗
2021-11-09	CuraSen Therapeutics, Inc.	CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease curasen.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	CST-103	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04935762 ↗
Route	Oral	“This is a Phase II, randomized, placebo-controlled, double-blind, crossover study to evaluate the effect of multiple oral doses of CST-103 in the presence of CST-107 on...” NCT04935762 ↗